Proliferative Glomerulonephritis with Monoclonal IgG Deposits and Refractory Ascites: Successful Treatment with Rituximab and Cell-free and Concentrated Ascites Reinfusion Therapy

A 49-year-old woman presented with nephrotic-range proteinuria, microhematuria, and moderate renal dysfunction. Diuretic-resistant refractory ascites associated with nephrotic syndrome were observed. Based on the histopathological findings, the patient was diagnosed with proliferative glomerulonephr...

Descripción completa

Detalles Bibliográficos
Autores principales: Takami, Norito, Inoue, Masatoshi, Kobayashi, Yoichi, Sugiyama, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449609/
https://www.ncbi.nlm.nih.gov/pubmed/35110486
http://dx.doi.org/10.2169/internalmedicine.8799-21
_version_ 1784784339264864256
author Takami, Norito
Inoue, Masatoshi
Kobayashi, Yoichi
Sugiyama, Yutaka
author_facet Takami, Norito
Inoue, Masatoshi
Kobayashi, Yoichi
Sugiyama, Yutaka
author_sort Takami, Norito
collection PubMed
description A 49-year-old woman presented with nephrotic-range proteinuria, microhematuria, and moderate renal dysfunction. Diuretic-resistant refractory ascites associated with nephrotic syndrome were observed. Based on the histopathological findings, the patient was diagnosed with proliferative glomerulonephritis with monoclonal immunoglobulin G deposits (PGNMID). Rituximab was administered due to steroid and immunosuppressive drug resistance, and partial remission was achieved after six months. Cell-free and concentrated ascites reinfusion therapy (CART) performed to treat the refractory ascites improved the ascites and anasarca. Rituximab successfully treated the PGNMID, while CART effectively treated the refractory ascites associated with nephrotic syndrome.
format Online
Article
Text
id pubmed-9449609
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-94496092022-09-19 Proliferative Glomerulonephritis with Monoclonal IgG Deposits and Refractory Ascites: Successful Treatment with Rituximab and Cell-free and Concentrated Ascites Reinfusion Therapy Takami, Norito Inoue, Masatoshi Kobayashi, Yoichi Sugiyama, Yutaka Intern Med Case Report A 49-year-old woman presented with nephrotic-range proteinuria, microhematuria, and moderate renal dysfunction. Diuretic-resistant refractory ascites associated with nephrotic syndrome were observed. Based on the histopathological findings, the patient was diagnosed with proliferative glomerulonephritis with monoclonal immunoglobulin G deposits (PGNMID). Rituximab was administered due to steroid and immunosuppressive drug resistance, and partial remission was achieved after six months. Cell-free and concentrated ascites reinfusion therapy (CART) performed to treat the refractory ascites improved the ascites and anasarca. Rituximab successfully treated the PGNMID, while CART effectively treated the refractory ascites associated with nephrotic syndrome. The Japanese Society of Internal Medicine 2022-02-01 2022-08-15 /pmc/articles/PMC9449609/ /pubmed/35110486 http://dx.doi.org/10.2169/internalmedicine.8799-21 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Takami, Norito
Inoue, Masatoshi
Kobayashi, Yoichi
Sugiyama, Yutaka
Proliferative Glomerulonephritis with Monoclonal IgG Deposits and Refractory Ascites: Successful Treatment with Rituximab and Cell-free and Concentrated Ascites Reinfusion Therapy
title Proliferative Glomerulonephritis with Monoclonal IgG Deposits and Refractory Ascites: Successful Treatment with Rituximab and Cell-free and Concentrated Ascites Reinfusion Therapy
title_full Proliferative Glomerulonephritis with Monoclonal IgG Deposits and Refractory Ascites: Successful Treatment with Rituximab and Cell-free and Concentrated Ascites Reinfusion Therapy
title_fullStr Proliferative Glomerulonephritis with Monoclonal IgG Deposits and Refractory Ascites: Successful Treatment with Rituximab and Cell-free and Concentrated Ascites Reinfusion Therapy
title_full_unstemmed Proliferative Glomerulonephritis with Monoclonal IgG Deposits and Refractory Ascites: Successful Treatment with Rituximab and Cell-free and Concentrated Ascites Reinfusion Therapy
title_short Proliferative Glomerulonephritis with Monoclonal IgG Deposits and Refractory Ascites: Successful Treatment with Rituximab and Cell-free and Concentrated Ascites Reinfusion Therapy
title_sort proliferative glomerulonephritis with monoclonal igg deposits and refractory ascites: successful treatment with rituximab and cell-free and concentrated ascites reinfusion therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449609/
https://www.ncbi.nlm.nih.gov/pubmed/35110486
http://dx.doi.org/10.2169/internalmedicine.8799-21
work_keys_str_mv AT takaminorito proliferativeglomerulonephritiswithmonoclonaliggdepositsandrefractoryascitessuccessfultreatmentwithrituximabandcellfreeandconcentratedascitesreinfusiontherapy
AT inouemasatoshi proliferativeglomerulonephritiswithmonoclonaliggdepositsandrefractoryascitessuccessfultreatmentwithrituximabandcellfreeandconcentratedascitesreinfusiontherapy
AT kobayashiyoichi proliferativeglomerulonephritiswithmonoclonaliggdepositsandrefractoryascitessuccessfultreatmentwithrituximabandcellfreeandconcentratedascitesreinfusiontherapy
AT sugiyamayutaka proliferativeglomerulonephritiswithmonoclonaliggdepositsandrefractoryascitessuccessfultreatmentwithrituximabandcellfreeandconcentratedascitesreinfusiontherapy

Ejemplares similares